Bradyarrhythmia induced by amiodarone-sofosbuvir co-administration

Excerpt

Amiodarone is widely used in the management of patients with supraventricular and ventricular arrhythmias; it is considered as a class III antiarrhythmic agent according to the Vaughan-Williams classification [1]. However, this molecule has a narrow therapeutic index and thus a significant risk of toxicity. The most prevalent adverse events related to amiodarone therapy such as gastrointestinal, pulmonary, and thyroid toxicity are well documented. Moreover, the major amiodarone drug interactions were seen mainly with molecules commonly used in cardiovascular field [2]. Nonetheless, we would like to point out some concerns about a less known drug-drug interaction, namely bradyarrhythmia, which was seen with regimens approved for the treatment of chronic hepatitis C virus (HCV) disease. …